Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AVIR
SELLAtea Pharmaceuticals, Inc. · Healthcare · United States · $379M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for life-threatening viral infections like COVID-19 and dengue. Its proprietary nucleotide prodrug platform for antiviral drug discovery offers potential for broad-spectrum antiviral activity and addresses significant unmet medical needs. Atea is a specialized biotech company dedicated to antiviral drug development, with a focus on novel mechanisms of action.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 30.2M | — |
| EPS | 1.46 | -1.39 | -1.63 | -2.00 | -1.94 | — | -2.06 | -1.93 | -1.39 | — |
| Shares | — | 83.3M | 83.4M | 84.5M | 78.1M | -6.2% | 80.0M | — | — | — |
| Debt | — | 3.1M | 2.4M | 1.6M | 0.8M | -35.4% | 0.6M | — | — | — |
| Equity | — | 640.6M | 555.2M | 438.9M | 275.4M | -24.5% | — | — | — | — |
| Op CF | — | -121.0M | -85.4M | -135.5M | -132.0M | — | -147.9M | — | — | — |
| Inv CF | — | -455.4M | 40.3M | 56.1M | 188.8M | — | — | — | — | — |
| Fin CF | — | 0.4M | 0.3M | 0.3M | -25.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVIR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc.(you) | $379M | 29 | SELL |
| TENX | Tenax Therapeutics, Inc. | $385M | 28 | SELL |
| IPSC | Century Therapeutics, Inc. | $381M | 28 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
| SGMT | Sagimet Biosciences Inc. | $437M | 30 | SELL |
| CCCC | C4 Therapeutics, Inc. | $376M | 34 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 28 | SELL |
| XFOR | X4 Pharmaceuticals, Inc. | $363M | 33 | SELL |
| PRTC.L | PureTech Health plc | $421M | 26 | SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $372M | 23 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%